ARTICLE | Clinical News
VT-122: Phase II started
March 7, 2011 8:00 AM UTC
In December, Vicus began an open-label, U.S. Phase II trial to compare oral VT-122 plus Nexavar sorafenib vs. Nexavar alone in 80 patients with hepatocellular carcinoma (HCC). Bayer AG (Xetra:BAY, L...